Vol. 6 No. 3 (2026)
Reimbursement Reviews

Glofitamab (Columvi)

decorative image of the issue cover

Published March 5, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Glofitamab, 1 mg/mL, concentrate for solution for IV infusion.
  • Indication: COLUMVI (glofitamab for injection), in combination with gemcitabine and oxaliplatin, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).